Analyst Ratings for [CRTX] Cortexyme, Inc.

CRTX Cortexyme, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

1/27/22	Downgrades	Mkt Outperform Mkt Perform	X
CRTX Cortexyme JMP Securities
10/27/21	Downgrades	Neutral Underperform	X
CRTX Cortexyme BofA Securities
$58 $15
4/26/21	Resumed	Underperform	X
CRTX Cortexyme Credit Suisse
$14
2/17/21	Downgrades	Buy Hold	X
CRTX Cortexyme Jefferies
$59 $34
6/3/19	Initiated	Neutral	X
CRTX Cortexyme BofA/Merrill
$28
6/3/19	Initiated	Buy	X
CRTX Cortexyme Canaccord Genuity
$42
6/3/19	Initiated	Underperform	X
CRTX Cortexyme Credit Suisse
$14
6/3/19	Initiated	Mkt Outperform	X
CRTX Cortexyme JMP Securities
$53